DK1125929T3 - Fremgangsmåde til fremstilling af (-)-(2R,4S)-4-[(3,5-bis-trifluormethyl-benzyl)-methoxycarbonylamino]-2-ethyl-6-trifluormethyl-3,4-dihydro-2H-quinolin-1-carboxylsyreethylester - Google Patents

Fremgangsmåde til fremstilling af (-)-(2R,4S)-4-[(3,5-bis-trifluormethyl-benzyl)-methoxycarbonylamino]-2-ethyl-6-trifluormethyl-3,4-dihydro-2H-quinolin-1-carboxylsyreethylester

Info

Publication number
DK1125929T3
DK1125929T3 DK00310064T DK00310064T DK1125929T3 DK 1125929 T3 DK1125929 T3 DK 1125929T3 DK 00310064 T DK00310064 T DK 00310064T DK 00310064 T DK00310064 T DK 00310064T DK 1125929 T3 DK1125929 T3 DK 1125929T3
Authority
DK
Denmark
Prior art keywords
trifluoromethyl
methoxycarbonylamino
quinoline
dihydro
benzyl
Prior art date
Application number
DK00310064T
Other languages
Danish (da)
English (en)
Inventor
David Burns Damon
Robert Wayne Dugger
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1125929T3 publication Critical patent/DK1125929T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00310064T 1999-11-30 2000-11-13 Fremgangsmåde til fremstilling af (-)-(2R,4S)-4-[(3,5-bis-trifluormethyl-benzyl)-methoxycarbonylamino]-2-ethyl-6-trifluormethyl-3,4-dihydro-2H-quinolin-1-carboxylsyreethylester DK1125929T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16796799P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
DK1125929T3 true DK1125929T3 (da) 2006-04-03

Family

ID=22609556

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00310064T DK1125929T3 (da) 1999-11-30 2000-11-13 Fremgangsmåde til fremstilling af (-)-(2R,4S)-4-[(3,5-bis-trifluormethyl-benzyl)-methoxycarbonylamino]-2-ethyl-6-trifluormethyl-3,4-dihydro-2H-quinolin-1-carboxylsyreethylester

Country Status (44)

Country Link
US (1) US6313142B1 (enExample)
EP (1) EP1125929B1 (enExample)
JP (1) JP3579345B2 (enExample)
KR (1) KR100408177B1 (enExample)
CN (1) CN1173953C (enExample)
AP (1) AP2000002011A0 (enExample)
AR (1) AR029775A1 (enExample)
AT (1) ATE315028T1 (enExample)
AU (1) AU784694B2 (enExample)
BG (1) BG105009A (enExample)
BR (1) BR0005636A (enExample)
CA (1) CA2327029C (enExample)
CO (1) CO5261552A1 (enExample)
CY (1) CY1104989T1 (enExample)
CZ (1) CZ20004407A3 (enExample)
DE (1) DE60025317T2 (enExample)
DK (1) DK1125929T3 (enExample)
DZ (1) DZ3079A1 (enExample)
EA (1) EA003668B1 (enExample)
EE (1) EE200000659A (enExample)
ES (1) ES2254109T3 (enExample)
GE (1) GEP20022798B (enExample)
GT (1) GT200000190A (enExample)
HN (1) HN2000000203A (enExample)
HR (1) HRP20000804A2 (enExample)
HU (1) HUP0004747A3 (enExample)
ID (1) ID28489A (enExample)
IL (1) IL139849A (enExample)
IS (1) IS5715A (enExample)
MA (1) MA25223A1 (enExample)
NO (1) NO20006039L (enExample)
NZ (1) NZ508509A (enExample)
OA (1) OA11494A (enExample)
PA (1) PA8503801A1 (enExample)
PE (1) PE20010913A1 (enExample)
PL (1) PL344208A1 (enExample)
SG (1) SG102603A1 (enExample)
SK (1) SK17792000A3 (enExample)
TN (1) TNSN00230A1 (enExample)
TW (1) TW591016B (enExample)
UA (1) UA65615C2 (enExample)
UY (1) UY26451A1 (enExample)
YU (1) YU71500A (enExample)
ZA (1) ZA200006947B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
IL162533A0 (en) * 2001-12-19 2005-11-20 Atherogenics Inc Chalcone derivatives and their use to treat diseases
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
ATE410521T1 (de) * 2002-04-11 2008-10-15 Roar Holding Llc Ex-vivo-verfahren zur bestimmung der cetp- aktivität und der wirksamkeit der behandlung von herzerkrankungen
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
PL376156A1 (en) * 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
WO2004056727A2 (en) * 2002-12-19 2004-07-08 Atherogenics, Inc. Process of making chalcone derivatives
EP1961419B1 (en) 2002-12-20 2010-03-24 Pfizer Products Inc. Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP1601655A2 (en) * 2003-03-04 2005-12-07 Takasago International Corporation Method for producing optically active amines
AU2004222436A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
PT1603553E (pt) * 2003-03-17 2012-02-03 Japan Tobacco Inc Composições farmacêuticas de inibidores de cetp
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
PL1670768T3 (pl) * 2003-10-08 2010-01-29 Lilly Co Eli Związki i sposoby leczenia dyslipidemii
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
WO2006069162A1 (en) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
BRPI0608553A2 (pt) * 2005-02-24 2010-01-12 Millennium Pharm Inc antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
CN101429160B (zh) * 2007-11-06 2011-10-19 上海药明康德新药开发有限公司 一种1-r-4-氨基-1,2,3,4-四氢喹啉的合成方法
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
PE20251749A1 (es) 2022-07-05 2025-07-09 Newamsterdam Pharma B V Sales de obicetrapib y procesos para su fabricacion y productos intermedios de estos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7870M (enExample) * 1968-11-08 1970-04-27
US3971789A (en) 1972-10-21 1976-07-27 John Wyeth & Brother Limited O-(4-Quinolylamino)benzamides
GB8432091D0 (en) 1984-12-19 1985-01-30 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US4839368A (en) 1986-05-02 1989-06-13 Mochida Pharmaceutical Co., Ltd. 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.

Also Published As

Publication number Publication date
PE20010913A1 (es) 2001-09-10
DZ3079A1 (fr) 2004-10-24
CA2327029A1 (en) 2001-05-30
HUP0004747A2 (hu) 2001-10-28
EA200001129A3 (ru) 2001-10-22
EE200000659A (et) 2001-08-15
IL139849A0 (en) 2002-02-10
YU71500A (sh) 2003-02-28
DE60025317T2 (de) 2006-08-03
PL344208A1 (en) 2001-06-04
MA25223A1 (fr) 2001-07-02
EP1125929B1 (en) 2006-01-04
UA65615C2 (uk) 2004-04-15
JP3579345B2 (ja) 2004-10-20
NO20006039D0 (no) 2000-11-29
EA003668B1 (ru) 2003-08-28
HN2000000203A (es) 2001-06-13
JP2001163859A (ja) 2001-06-19
CO5261552A1 (es) 2003-03-31
ES2254109T3 (es) 2006-06-16
CZ20004407A3 (cs) 2002-06-12
US6313142B1 (en) 2001-11-06
ID28489A (id) 2001-05-31
SK17792000A3 (sk) 2002-10-08
AP2000002011A0 (en) 2000-12-31
KR20010052012A (ko) 2001-06-25
OA11494A (en) 2004-05-07
ATE315028T1 (de) 2006-02-15
AR029775A1 (es) 2003-07-16
CA2327029C (en) 2005-08-09
AU784694B2 (en) 2006-06-01
ZA200006947B (en) 2002-05-27
HUP0004747A3 (en) 2002-12-28
SG102603A1 (en) 2004-03-26
HU0004747D0 (enExample) 2001-02-28
NO20006039L (no) 2001-05-31
DE60025317D1 (de) 2006-03-30
BR0005636A (pt) 2001-07-17
EP1125929A1 (en) 2001-08-22
CN1173953C (zh) 2004-11-03
GEP20022798B (en) 2002-09-25
PA8503801A1 (es) 2002-07-30
TNSN00230A1 (fr) 2005-11-10
CY1104989T1 (el) 2010-03-03
HRP20000804A2 (en) 2001-06-30
GT200000190A (es) 2002-04-27
NZ508509A (en) 2001-06-29
KR100408177B1 (ko) 2003-12-01
IL139849A (en) 2006-10-31
TW591016B (en) 2004-06-11
UY26451A1 (es) 2001-06-29
IS5715A (is) 2001-05-31
HK1038007A1 (en) 2002-03-01
BG105009A (en) 2001-11-30
AU7178900A (en) 2001-05-31
CN1302800A (zh) 2001-07-11
EA200001129A2 (ru) 2001-06-25

Similar Documents

Publication Publication Date Title
ATE315028T1 (de) Herstellungsverfahren für (-)-(2r,4s)-4-((3,5-bis-trifluoromethyl-benzyl) methoxycarbonylamino)-2- ethyl-6-trifluoromethyl-3,4-dihydro-2h-chinolin 1-carbonylsäureethylester
CA2473991A1 (en) Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
DK1353917T3 (da) Ny fremgangsmåde til syntesen af 5-(4-fluorphenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrol-3-carboxylsyre phenylamid
TR199900428T2 (xx) 1,4-Heterosiklik metaloproteaz inhibit�rleri.
DE60000708D1 (de) Verfahren zur Herstellung von (Meth)acrylsäure
TR199900382T2 (xx) Heterosiklik metaloproteaz inhibit�rleri.
DE60021308D1 (de) Verfahren zur Herstellung von (Meth)acrylsäure
TR199800669A3 (tr) Akrilonitrilin polimerizasyonu için islem
DK1147075T3 (da) Fremgangsmåde til fremstilling af L-phenylephrinhydrochlorid
ID24863A (id) Proses pembuatan vinil ester dari butenoligomeran
DE60001599D1 (de) Verfahren zur Herstellung von cis-1-2-[4-(6-Methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl-pyrrolidin
TR200000720T2 (tr) Kuinolin türevlerinin sentezi için metod.
DK0946514T3 (da) Fremgangsmåde til fremstilling af n-substituerede 3-hydroxypyrazoler
DK1037613T3 (da) Fremgangsmåde til fremstilling af farmaceutiske formuleringer, der indeholder en ekstrakt
DE69936186D1 (de) Dihydroartemisinin-Formulierung zur Behandlung von verschiedenen Typen von Malaria
DE60043610D1 (de) Verfahren zur herstellung von l-lysin
DE60003807D1 (de) Enantiomere von mercaptolactonen und verfahren zu ihrer herstellung
NO20021727L (no) Fremgangsmåte for fremstilling av 3,4-metylen-dioksy- mandelisk syre
DE60221500D1 (de) Verfahren zur herstellung von fibraten
DK1493442T3 (da) Reboxetin til behandling af perifer neuropati
DE50100478D1 (de) Verfahren zur Herstellung von Esterquats
DK0899262T3 (da) Fremgangsmåde til fremstilling af heteroarylcarboxylamider og -estere
NO20016390D0 (no) Fremgangsmåte for fremstilling av (-)-(1S,4R) N-beskyttede 4- amino-2-cyklopenten-1-karboksylatestere
MY134349A (en) Preparation of anhydrous cetp inhibitor
NO20002944D0 (no) FremgangsmÕte for fremstilling av isopropylmetyl-(2-)3-n- propolsyfenoksy)etyl)amin